Who are Hyperpolarized xenon 129's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): 129-Xe.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hyperpolarized-xenon-129.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Hyperpolarized xenon 129 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hyperpolarized xenon 129 (Hyperpolarized xenon 129) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hyperpolarized gas contrast agent. Area: Pulmonary/Respiratory Imaging.

marketed Hyperpolarized gas contrast agent Pulmonary/Respiratory Imaging Small molecule Live · refreshed every 30 min

Target snapshot

Hyperpolarized xenon 129 (Hyperpolarized xenon 129) — Y. Michael Shim, MD. Hyperpolarized xenon-129 is an inhaled contrast agent that enhances lung MRI by providing increased signal from ventilated airspaces, enabling detailed visualization of pulmonary function and gas exchange.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Hyperpolarized xenon 129 TARGET	Hyperpolarized xenon 129	Y. Michael Shim, MD	marketed	Hyperpolarized gas contrast agent
129-Xe	129-Xe	Children's Hospital Medical Center, Cincinnati	marketed	Hyperpolarized gas contrast agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hyperpolarized gas contrast agent class)

Children's Hospital Medical Center, Cincinnati · 1 drug in this class
Y. Michael Shim, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hyperpolarized xenon 129 — Competitive Intelligence Brief. https://druglandscape.com/ci/hyperpolarized-xenon-129. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing